Issue link: https://www.e-digitaleditions.com/i/1349974
Tablets & Capsules March/April 2021 32G of the world were included in the meta-analyses. Using these results, the scientists have calculated that if all Germans over the age of 50 were to take vitamin D supplements, the country could possibly avoid up to 30,000 cancer deaths per year and save in heathcare costs. To learn more, visit www.dkfz.de/en. Vitamin D may reduce cancer mortality rate HEIDELBERG, Germany—Three recent meta-analyses of clinical stud- ies have concluded that vitamin D supplementation is associated with about a 13 percent reduction in the mortality rate from cancer of all types, according to scientists at the German Cancer Research Center (DKFZ). Only methodologically high-qual- ity randomized trials from all parts nutra news Kerry announces intent to acquire Biosearch Life and partnership with PFI DUBLIN, Ireland—Kerry Group announced its intention to acquire Biosearch Life, Granada, Spain, a bio- technology solutions provider. The company has an extensive range of pro- biotics including probiotics obtained from human breast milk (Hereditum), scientifically backed innovative botan- ical extracts (Exxentia), and natural omega-3 (Eupoly-3). Kerry also announced a strategic licensing partnership with Pharma Foods International (PFI), Kyoto, Japan, for the development, applica- tion, and global sales of a joint health ingredient technology for dietary sup- plements and functional foods and beverages. PFI develops innovative ingredients from natural food origins for functional, nutraceutical, cosmetic, and pharmaceutical applications. The partnership and licensing agreement provides Kerry access to PFI's joint health technology. Aker BioMarine collaborates with university on EPA/DHA study LYSAKER, Norway—Aker Bio- Marine has entered into a research collaboration with Université de Sherbrooke Department of Medicine, Sherbrooke, QC, to investigate if lys- ophosphatidylcholine (LPC)-bound EPA/DHA is effective in preventing cognitive decline associated with Alzheimer's disease. The study will use different EPA / DHA formula- tions, including Aker BioMarine's krill-based LPC EPA /DHA product (Lysoveta), to investigate if LPC is a superior source of these fatty acids in populations genetically at-risk for Alzheimer's disease compared to EPA/ DHA from fish oil.